Glenmark Pharmaceuticals Launches Vancomycin Hydrochloride Injection in the US Market
Elmwood Park, New Jersey, May 18, 2026 — Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Vancomycin Hydrochloride for Injection USP, available in 500 mg/vial and 1 g/vial concentrations. The company stated that Glenmark's Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial manufactured by Fresenius Kabi USA, LLC.The launch adds the product to Glenmark's portfolio, solidifying its presence in the U.S. pharmaceutical market.
According to IQVIA sales data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP market achieved annual sales of approximately $37.9 million. This market figure includes brand and all available therapeutic equivalents.
Commenting on the development, Marc Kikuchi, President & Business Head, North America, said that the launch reflects Glenmark's ongoing commitment to broadening access to quality, affordable medicines in the U.S. He added that the launch strengthens the company's injectable portfolio and reinforces its focus on providing reliable treatment options to both healthcare providers and patients.
Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company focused on innovation and accessibility. The company delivers a diversified portfolio across branded, innovative, generics, and consumer health products, with a specific emphasis on respiratory, dermatology, and oncology treatments.
GLENMARK Stock Price Movement
As of 9:14 AM, shares of GLENMARK PHARMACEUTICALS LIMITED are edging higher in the pre-open session, gaining 0.16% to reach ₹2329.7. The stock is seeing moderate activity in the morning session, supported by a total traded volume of 1,036 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.